319 related articles for article (PubMed ID: 31177392)
1. Chemotherapy-induced nausea and vomiting control in pediatric patients receiving ifosfamide plus etoposide: a prospective, observational study.
Patel P; Lavoratore SR; Flank J; Kemp M; Vennettilli A; Vol H; Taylor T; Zelunka E; Maloney AM; Nathan PC; Dupuis LL
Support Care Cancer; 2020 Feb; 28(2):933-938. PubMed ID: 31177392
[TBL] [Abstract][Full Text] [Related]
2. Poor chemotherapy-induced nausea and vomiting control in children receiving intermediate or high dose methotrexate.
Vol H; Flank J; Lavoratore SR; Nathan PC; Taylor T; Zelunka E; Maloney AM; Lee Dupuis L
Support Care Cancer; 2016 Mar; 24(3):1365-71. PubMed ID: 26335406
[TBL] [Abstract][Full Text] [Related]
3. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy.
Chan A; Low XH; Yap KY
J Manag Care Pharm; 2012 Jun; 18(5):385-94. PubMed ID: 22663171
[TBL] [Abstract][Full Text] [Related]
5. The burden of chemotherapy-induced nausea and vomiting in children receiving hematopoietic stem cell transplantation conditioning: a prospective study.
Flank J; Sparavalo J; Vol H; Hagen L; Stuhler R; Chong D; Courtney S; Doyle JJ; Gassas A; Schechter T; Dupuis LL
Bone Marrow Transplant; 2017 Sep; 52(9):1294-1299. PubMed ID: 28581463
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
7. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
[TBL] [Abstract][Full Text] [Related]
9. Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis.
Patel P; Robinson PD; Wahib N; Cheung P; Wong T; Cabral S; Parker A; Cohen M; Devine K; Gibson P; Holdsworth MT; Neumann E; Orsey A; Phillips R; Spinelli D; Thackray J; van de Wetering M; Woods D; Sung L; Dupuis LL
Support Care Cancer; 2022 Nov; 30(11):8855-8869. PubMed ID: 35953731
[TBL] [Abstract][Full Text] [Related]
10. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes.
Liau CT; Chu NM; Liu HE; Deuson R; Lien J; Chen JS
Support Care Cancer; 2005 May; 13(5):277-86. PubMed ID: 15770489
[TBL] [Abstract][Full Text] [Related]
11. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.
Hilarius DL; Kloeg PH; van der Wall E; van den Heuvel JJ; Gundy CM; Aaronson NK
Support Care Cancer; 2012 Jan; 20(1):107-17. PubMed ID: 21258948
[TBL] [Abstract][Full Text] [Related]
13. Incidence of nausea and vomiting in breast cancer patients treated with anthracycline plus cyclophosphamide-based chemotherapy regimens in Italy: NAVY observational study.
De Laurentiis M; Bonfadini C; Lorusso V; Cilenti G; Di Rella F; Altavilla G; Otero M; Ardizzoia A; Marchetti P; Peverelli G; Amoroso D; Vecchio S; Fiorio E; Orecchia S
Support Care Cancer; 2018 Dec; 26(12):4021-4029. PubMed ID: 29943152
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131).
Nishio S; Aihara S; Shimokawa M; Fujishita A; Taniguchi S; Hachisuga T; Yanazume S; Kobayashi H; Murakami F; Numa F; Kotera K; Okura N; Toki N; Yokoyama M; Ushijima K
J Gynecol Oncol; 2018 Sep; 29(5):e77. PubMed ID: 30022637
[TBL] [Abstract][Full Text] [Related]
16. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
[TBL] [Abstract][Full Text] [Related]
17. 2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children.
Dupuis LL; Sung L; Molassiotis A; Orsey AD; Tissing W; van de Wetering M
Support Care Cancer; 2017 Jan; 25(1):323-331. PubMed ID: 27565788
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine for prevention of chemotherapy-induced nausea and vomiting in children and adolescents: a multi-center, feasibility study.
Flank J; Schechter T; Gibson P; Johnston DL; Orsey AD; Portwine C; Sung L; Dupuis LL
Support Care Cancer; 2018 Feb; 26(2):549-555. PubMed ID: 28856448
[TBL] [Abstract][Full Text] [Related]
19. Nausea and vomiting in children and adolescents receiving intrathecal methotrexate: A prospective, observational study.
Flank J; Nadeem K; Moledina S; Khanna M; Schindera C; Punnett A; Dupuis LL
Pediatr Blood Cancer; 2017 Oct; 64(10):. PubMed ID: 28500750
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis.
Chow R; Yin LB; Baqri W; Huang R; Boldt G; Younus J; Lock M; Prsic E; Zimmermann C; Herrstedt J
Support Care Cancer; 2023 Aug; 31(8):505. PubMed ID: 37535218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
